A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 8,135,804 shares of BCRX stock, worth $68.6 Million. This represents 1.06% of its overall portfolio holdings.

Number of Shares
8,135,804
Previous 4,995,000 62.88%
Holding current value
$68.6 Million
Previous $25.4 Million 98.15%
% of portfolio
1.06%
Previous 0.52%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.13 - $6.79 $13 Million - $21.3 Million
3,140,804 Added 62.88%
8,135,804 $50.3 Million
Q1 2024

May 15, 2024

BUY
$4.89 - $7.65 $2.23 Million - $3.48 Million
455,475 Added 10.03%
4,995,000 $25.4 Million
Q4 2023

Feb 14, 2024

BUY
$4.98 - $6.77 $6.24 Million - $8.49 Million
1,253,525 Added 38.15%
4,539,525 $27.2 Million
Q3 2023

Nov 14, 2023

BUY
$6.71 - $7.92 $13.2 Million - $15.6 Million
1,964,000 Added 148.56%
3,286,000 $23.3 Million
Q2 2023

Aug 14, 2023

SELL
$6.96 - $8.81 $10 Million - $12.7 Million
-1,443,000 Reduced 52.19%
1,322,000 $9.31 Million
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $22 Million - $32.7 Million
2,765,000 New
2,765,000 $23.1 Million
Q2 2022

Aug 15, 2022

SELL
$7.89 - $17.88 $7.98 Million - $18.1 Million
-1,012,000 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $7.79 Million - $13.3 Million
-674,140 Reduced 39.98%
1,012,000 $16.5 Million
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $16.2 Million - $22.4 Million
1,451,497 Added 618.6%
1,686,140 $23.4 Million
Q3 2021

Nov 15, 2021

SELL
$14.21 - $17.65 $37 Million - $45.9 Million
-2,600,357 Reduced 91.72%
234,643 $3.37 Million
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $2.18 Million - $3.96 Million
229,620 Added 8.81%
2,835,000 $44.8 Million
Q1 2021

May 17, 2021

SELL
$7.37 - $13.61 $23.8 Million - $44 Million
-3,230,430 Reduced 55.36%
2,605,380 $26.5 Million
Q4 2020

Feb 16, 2021

BUY
$3.37 - $8.61 $4.65 Million - $11.9 Million
1,379,291 Added 30.95%
5,835,810 $43.5 Million
Q2 2020

Aug 14, 2020

SELL
$1.9 - $5.61 $373,173 - $1.1 Million
-196,407 Reduced 4.22%
4,456,519 $21.2 Million
Q1 2020

May 15, 2020

SELL
$1.6 - $4.11 $2.76 Million - $7.08 Million
-1,722,217 Reduced 27.01%
4,652,926 $9.31 Million
Q4 2019

Feb 14, 2020

BUY
$1.59 - $3.45 $5.72 Million - $12.4 Million
3,600,500 Added 129.76%
6,375,143 $22 Million
Q3 2019

Nov 14, 2019

SELL
$2.5 - $3.73 $8.8 Million - $13.1 Million
-3,518,337 Reduced 55.91%
2,774,643 $7.95 Million
Q2 2019

Aug 14, 2019

SELL
$2.91 - $9.15 $711,745 - $2.24 Million
-244,586 Reduced 3.74%
6,292,980 $23.9 Million
Q1 2019

May 15, 2019

SELL
$7.38 - $9.72 $2.75 Million - $3.63 Million
-373,223 Reduced 5.4%
6,537,566 $53.2 Million
Q3 2018

Nov 14, 2018

BUY
$5.52 - $7.99 $4.68 Million - $6.77 Million
847,293 Added 13.97%
6,910,789 $52.7 Million
Q2 2018

Aug 14, 2018

SELL
$4.6 - $6.52 $5.99 Million - $8.5 Million
-1,302,964 Reduced 17.69%
6,063,496 $34.7 Million
Q1 2018

May 15, 2018

BUY
$4.35 - $5.82 $665,841 - $890,849
153,067 Added 2.12%
7,366,460 $35.1 Million
Q4 2017

Feb 14, 2018

BUY
$4.16 - $5.33 $9.31 Million - $11.9 Million
2,237,942 Added 44.98%
7,213,393 $35.4 Million
Q3 2017

Nov 13, 2017

BUY
$4.1 - $5.97 $20.4 Million - $29.7 Million
4,975,451
4,975,451 $26.1 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.57B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.